I reported previously (three times) on Israel’s Enlivex and its Allocetra / Apocell treatment to prevent Graft vs Host Disease – a common problem after bone marrow transplants. Elivex has just received $8 million of funding which will help it progress to Phase 3 trials.
https://www.calcalistech.com/ctech/articles/0,7340,L-3721734,00.html